-
MyChart
Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
-
Request an Appointment
Request an Appointment
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information - Donate Today

MENU
Investigational Cancer Therapeutics
Funda Meric-Bernstam, M.D.
Department Chair
Phase I Clinical Trials Program
The Department of Investigational Cancer Therapeutics conducts broad phase I studies across disease boundaries and molecular targets. We strive to provide outstanding patient care while performing innovative phase I trials with new drugs that may eventually improve the management of cancer.
Under the leadership of Department Chair Dr. Funda Meric-Bernstam, Deputy Department Chair Dr. David Hong, and Department Administrator Yagut Retondo, our program has become a centralized resource for patients, physicians and scientists who are looking for new experimental phase I therapies that may eventually represent advances in cancer research and treatment.
Goals
- To provide novel cancer treatment options to patients with cancer
- To improve treatment options for patients with cancer through research and discovery
- To provide education, instruction, and training for the next generation of clinical researchers through fellowship and publications
You also can learn about the Clinical Center for Targeted Therapy, which is dedicated to providing excellent care to our patients by bringing the newest agents for cancer treatment more quickly from the laboratory to clinical trials.
Education and Training
The Investigational Cancer Therapeutics Fellowship offers a one-, two-,
or three-year experience in early drug development.
Contact us
Telephone: 713-563-0181
Office hours
Monday-Friday, 8:00 a.m. - 5:00 p.m.
Physical address (for deliveries):
1400 Holcombe Boulevard
Unit 455
Faculty Center 8th Floor
Houston, TX 77030
Mailing address:
(Name)
UT MD Anderson Cancer Center
Department of Investigational Cancer Therapeutics, Unit 455
PO Box 301402
Houston, TX 77230-1402